Radiotherapy for marginally resected, un-resectable or recurrent giant cell tumor of the bone: a rare cancer network study

Sumita Bhatia, Leszek Miszczyk, Martine Roelands, Tan Dat Nguyen, Tom Boterberg, Phillip Poortmans, Laura Vallow, Fazilet O. Dincbas, Yasmin Lassen-Ramshad, Maikel Botros, Robert C. Miller

1 Mayo Clinic, Rochester, MN, USA, 2 MSC Memorial Cancer Center, Gliwice, Poland, 3 Institut Jules Bordet, Brussels, Belgium, 4 Institut Jean Godinot, Reims, France, 5 Ghent University Hospital, Ghent, Belgium; 6 Bernard Institut Verbeeten, Tilburg, The Netherlands; 7 Mayo Clinic, Jacksonville, Florida, USA; 8 Cerrahpas Medical School, Istanbul University, Turkey; 9 Centre Francois Baclesse, Esch-sur-Alzette, Luxembourg; 10 Quillen College of Medicine-East Tennessee State University, Johnson City, Tennessee, USA

Abstract

The role of radiotherapy for local control of marginally resected, un-resectable, and recurrent giant cell tumors of bone (GCToB) has not been well defined. The number of patients affected by this rare disease is low. We present a series of 58 patients with biopsy proven GCToB who were treated with radiation therapy. A retrospective review of the role of radiotherapy in the treatment of GCToB was conducted in participating institutions of the Rare Cancer Network. Eligibility criteria consisted of the use of radiotherapy for marginally resected, un-resectable, and recurrent GCToB. Fifty-eight patients with biopsy proven GCToB were analyzed from 9 participating North American and European institutions. Forty-five patients had a primary tumor and 13 patients had a recurrent tumor. Median radiation dose was 50 Gy in a median of 25 fractions. Indication for radiation therapy was marginally resection in 33 patients, un-resectable tumor in 13 patients, recurrence in 9 patients and palliation in 2 patients. Median tumor size was 7.0 cm. A significant proportion of the tumors were due to location adjacent to critical structures that would compromise function. Primary study endpoints included local failure (LF) and overall survival (OS) rates. Secondary endpoints included toxicity, secondary malignancy occurrence, and prognostic factors. The Kaplan-Meier actuarial method was used to calculate survivals and tumor failures. Log-Rank testing was used to determine prognostic factors. This study was approved by the Mayo Foundation Institutional Review Board and at each participating site independently. Each participating site independently. Each participating site independently.

Results

Patient and tumor characteristics

A total of 58 patients with biopsy proven GCToB of histology ICD-0-3-92501 and 92503 were analyzed from European and North American academic centers (Table 1). Forty-five patients had a newly diagnosed GCToB with a median number of tumors at presentation of 1 (range 1 to 2). Thirteen patients had a recurrent tumor with a median number of localizations at presentation of 1 (range 1 to 4). Median age was 31 years (range 12 to 84). Median tumor size was 7 cm (range 2 to 15 cm). A significant proportion of the tumors involved the long bones of the lower limb. In 55% of the cases, critical structures were involved, of which the sacral plexus was the most common one.

Treatment characteristics

Thirteen patients had an un-resectable tumor and therefore did not have surgery as a component of their treatment (Table 2). Of the patients who had surgery, 30 patients had a R1 resection and 26 patients had a R2 resection. R1 resection was defined as microscopic disease left behind and R2 defined as gross disease left behind at the time of surgery. Out of the 26 patients who underwent a R2 resection, the largest diameter of the residual tumor was known for 14 patients. The median diameter of residual disease after R2 resection was 9.5 cm (range 2.0 to 14.0 cm).

All patients received radiation between 1976 to 2007. Indications for radiotherapy were recurrent GCToB after prior therapy, un-resectable GCToB due to potential involvement of
adjacent critical structures, marginal resection of GCToB without critical structure involvement and other indications where the risk of recurrence was deemed high enough to warrant adjuvant or definitive radiotherapy. An additional two patients received treatment for palliation. The most common indication was marginal resection or residual tumor. Median radiation dose was 50Gy (range 20 to 64.8Gy). Median number of fractions was 25 (range 5 to 36 fractions). Median dose per fraction was 2Gy. Median energy used was 6MV photons (range 1.25 to 25). For purposes of analysis, a local RT field was defined as GTV plus a margin that was less than or equal to 4 cm to the geometric edge of the radiotherapy field.

**Overall survival**

Median follow up was 8 years (range 4 months to 28.2 years). Survival information was available on all 58 patients. Five-year overall survival was 94% (Figure 1). There were 5 deaths. Cause of death was GCToB in 2 patients, unknown in 1 patient.

**Disease free survival**

Data was available for 54 patients. Five-year disease free survival was 81% (Figure 2). Of the 10 patients with failures, 2 patients had distant failures, 7 patients had local failures and one patient had both local and distant failure.

**Local control**

Five year local control was 85% (Figure 3). Of the 7 local failures, 3 failures were salvaged successfully with surgery. All palliative patients achieved symptom relief with radiation. Eleven patients received chemotherapy.

**Toxicity**

Twenty-eight patients did not experience any acute toxicity. Of the patients who experienced toxicity, the most common acute toxicity consisted of grade 1-2 skin changes. None of the patients experienced grade 3 or higher acute toxicity. Forty-six patients did not suffer from any chronic toxicity. Of patients who experienced chronic toxicity, the most common chronic toxicity consisted of skin changes. Two patients experienced grade 3 toxicity. This consisted of grade 3 anovulatory toxicity in one patient and grade 3 irregular menses in the other patient.

One patient developed an adenocarcinoma of the uterine cervix as a possible secondary malignancy in the field of radiation.

**Prognostic factors**

Univariate analysis did not reveal an association between gender, histology, grade, tumor type, tumor location, tumor size, R1/R2 resection, radiation dose, or indication of radiation (Table 3). There was a trend for improved 5 year local control in patients less than 30.8 years when compared to the older group (96% compared to 73%). There was improved disease free survival and overall survival in the younger age group as well (96% compared to 65%) and (100% compared to 87%) respectively.

**Discussion**

Giant cell tumors of bone are locally aggressive tumors with little tendency for metastasis. The treatment of choice for these tumors, historically, has been surgical resection. In some cases, surgical resection can result in

---

**Table 1. Patient and tumor characteristics.**

| Characteristics          | Number of patients (%) |
|--------------------------|------------------------|
| Age                      |                        |
| Age > 30.8 years         | 27 (49)                |
| Age ≤ 30.8 years         | 28 (51)                |
| Gender                   |                        |
| Male                     | 30 (55)                |
| Female                   | 25 (45)                |
| Histology                |                        |
| 92501                    | 54 (93)                |
| 92503                    | 4 (7)                  |
| Grade                    |                        |
| Grade 1                  | 9 (35)                 |
| Grade 2                  | 13 (50)                |
| Grade 3                  | 4 (15)                 |
| Tumor Dimension          |                        |
| ≥4 cm                    | 35 (78)                |
| <4 cm                    | 10 (22)                |
| Tumor Type prior to treatment |                  |
| Primary                  | 45 (78)                |
| Recurrence               | 13 (22)                |
| Primary bones involved   |                        |
| Appendicular             | 28 (48)                |
| Axial                    | 30 (52)                |
| Primary bones involved by site |                    |
| Lower limb long bone     | 23 (40)                |
| Upper limb long bone     | 5 (9)                  |
| Lower limb small bone    | 0 (0)                  |
| Upper limb small bone    | 2 (3)                  |
| Craniofacial             | 2 (3)                  |
| Vertebral cervical       | 3 (5)                  |
| Vertebral thoracic/lumbar| 8 (14)                 |
| Rib/clavicle             | 1 (2)                  |
| Pelvic bones             | 10 (17)                |
| Bones lumbar to pelvic   | 4 (7)                  |
| Most critical structures involved |        |
| None                     | 26 (45)                |
| Craniofacial             | 2 (3)                  |
| Brain/Spinal Cord        | 7 (12)                 |
| Sacral Plexus            | 13 (22)                |
| Genitourinary tract      | 0 (0)                  |
| Joint                    | 4 (7)                  |
| Neurovascular structure  | 2 (3)                  |
| Other                    | 4 (7)                  |

**Table 2. Treatment and radiation therapy characteristics.**

| Characteristic                          | Number of patients (%) |
|-----------------------------------------|------------------------|
| Extent of resection                     |                        |
| R0                                      | 2 (3)                  |
| R1                                      | 30 (52)                |
| R2                                      | 26 (45)                |
| Indication for radiation                |                        |
| Marginal resection, residual tumor      | 33 (58)                |
| Unresectable due to critical structures  | 13 (23)                |
| Recurrence                              | 9 (16)                 |
| Palliation                              | 2 (4)                  |
| Radiation Dose                          |                        |
| >50 Gy                                  | 25 (43)                |
| ≤50 Gy                                  | 33 (57)                |
| Radiation fractions                     |                        |
| ≥25 fractions                           | 41 (71)                |
| <25 fractions                           | 17 (29)                |
| Radiation delivery                      |                        |
| Co-60                                    | 24 (44)                |
| Linear Accelerator                      | 22 (40)                |
| Co-60 and Linear Accelerator            | 3 (5)                  |
| Roentgen therapy (X-ray)                | 2 (4)                  |
| Other                                    | 4 (7)                  |
| Field description                       |                        |
| Local                                    | 48 (83)                |
| Wide                                     | 10 (17)                |
severe impairment. In other cases, the site of the tumor and the neighboring organs render them inoperable. However, marginal resections result in a high rates of recurrence, mostly occurring within the first couple of years, justifying the use of adjuvant therapy.

GCToB are well responsive to radiation therapy. Local control following adjuvant or primary radiation therapy has ranged from 69% to 90% according to recent studies. Our study reports a large published experience in the treatment of GCToB with radiotherapy. The use of radiotherapy in this study resulted in an 85% local control rate. We were unable to identify any significant prognostic factors except for age. Possible explanations for this prognostic factor could be selection bias and the choice for more aggressive surgery in younger patients.

Other studies of GCToB have identified size and location as having a significant impact on local control. Mischczuk et al. identified tumor size >4 cm as a negative prognostic factor for local control. Caudell et al. and Feignberg et al. identified recurrent tumors as a negative prognostic factor for local control. Feignberg et al. also identified a dose-effect relationship with radiation, which revealed a correlation between doses of 40 Gy or less and a failure in local control. Our analysis did not find any correlation with site, size or dose in terms of local control or outcome. This could possibly be explained by the high local control rate achieved in our study and the inability to identify a poor prognostic group. Additionally, the median radiation dose utilized was 50Gy.

Another possible explanation could be the heterogeneity of the patient population. This study confirms the safety and efficacy of radiation therapy as treatment for GCToB. The median follow up for patients within this study was 8 years (range 4 months to 28.2 years). To date, none of the patients in this study developed malignant transformation of the GCToB or a radiation induced sarcoma. It is important to note that one patient developed an adenocarcinoma of the uterine cervix after treatment of her GCToB. This can possibly be attributed to a secondary malignancy from use of radiation therapy.

This is a multi-institutional study that was retrospectively performed. The limitations include the retrospective nature, lack of uniform treatment and follow up as well as possible selection bias. However, despite these limitations, our results in a fairly large group of patients with this very uncommon disease confirm the findings of other studies in this rare disease site with the use of radiation therapy.

Our analysis did not find any correlation with site, size or dose in terms of local control or outcome. This could possibly be explained by the high local control rate achieved in our study and the inability to identify a poor prognostic group. Additionally, the median radiation dose utilized was 50Gy.

Table 3. Prognostic factors assessed on univariate analysis.

| Prognostic factor                      | Overall survival | Disease free survival | Local Control |
|---------------------------------------|------------------|-----------------------|---------------|
| Age                                   | .03              | .03                   | .09           |
| Gender                                | .69              | .42                   | .28           |
| Grade                                 | .14              | .68                   | .29           |
| Histology                             | .21              | .33                   | .42           |
| Tumor type (primary vs. recurrence)   | .15              | .45                   | .61           |
| Tumor location (appendicular vs. axial)| .94              | .15                   | .49           |
| Tumor size                            | .76              | .87                   | .45           |
| Extent of resection                   | .90              | .75                   | .89           |
| Indication for radiation              | .15              | .76                   | .78           |
| Radiation dose                        | .99              | .44                   | .60           |

All numbers represent P values.

References

1. Malone S, O’ Sullivan B, Catton C, et al. Long-Term Follow-up of Efficacy and Safety of megavoltage radiotherapy in high-risk giant cell tumors of bone. Int J Radiat Oncol Biol Phys 1995;33:689-94.
2. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-Cell Tumor of Bone. J Bone Joint Surg. 1987;69A:106-14.
3. Feigenberg SJ, Marcus RB, Zlotecki RA, et al. Radiation Therapy for Giant Cell Tumors of Bone. Clin Orthop Relat Res 2002;411:207-16.
4. Suite H, Spiro I. Radiation treatment of benign mesenchymal disease. Semin Radiat Oncol 1999;9:171-8.
5. Mendenhall WM, Zlotecki RA, Scarborough MT, et al. Giant cell tumor of bone. Am J Clin Oncol 2006;29:96-9.
6. Chakravarti A, Spiro IJ, Hug EB, et al. Megavoltage Radiation Therapy for Axial and Inoperable Giant-Cell Tumor of Bone. J Bone Joint Surg. 1999;81A:1566-73.
7. Nair MK, Jyothirmayi R. Radiation Therapy in the Treatment of Giant Cell Tumor of Bone. Int J Radiation Oncol Biol Phys. 1999;43:1065-1069.
8. Mischczuk L, Wydmanski J, Spindel J. Efficacy of Radiotherapy for Giant Cell Tumor of Bone: Given Either Postoperatively or as Sole Treatment. Int J Radiation Oncol Biol Phys. 2001; 49:1239-1242.
9. Ruka W, Rutkowski P, Morysinski T, et al. The Megavoltage Radiation Therapy in Treatment of Patients with Advanced or Difficult Giant Cell Tumors of Bone. Int J Radiat Oncol Biol Phys 2010;78:494-8.
10. Caudell JJ, Ballo MT, Zalgars GK, et al. Radiotherapy in the management of giant cell tumor of the bone. Int J Radiat Oncol Biol Phys 2003;57:158-65.